Member Info for Brand

From the link provided:

Brief Summary:
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.

Certainly seems to say phase 3

Stu saw too many positive posts and had to jump in to remind us of his trading 'strategy'

That's the other huge gold star for SNG, 15 years of safety data vs whatever the mad big pharma scientists have cooked up in the last 18 months. The market is more aware of what's in their drugs than ever before and INF-B is 'natural'

Re activ being 'adaptive' it probably isn't designed that way but imagine NIH turned to the US gov and said 'SNG works really well but we pitched the trial slightly wrong so we dropped it' - not a chance.

A good point well made Skip.

Would add to those saying 'it only works in breathless patients' to keep in mind this is a US govt trial, not a standard pharma trial - if it works in hospitalised breathless patients but isn't as significant in a home setting, it's not like there going to just drop it - they'll move SNG to an appropriate p3.

Sure wouldn't want to be out if Activ 2 is announced today. Will skyrocket imho. Gla.

The thing w this study is, if SNG doesn't quite fit the bill as an 'at home' treatment, but does knock it out of the park in hospitalised patients (like we know it does) - it's not like the US gov is just going to drop us. We'll be moved to an appropriate study and/or fast tracked for EUA. It is a cure for Covid after all! Can respect those looking to trade up their shares but that US news could drop at 1300 GMT anyday. (Even today) HOLD for me. Dyor etc.

1300 kickoff time looks like it's aimed at the US Market.

This isn't someone you hire if your planning to be taken over imho

The role holder will be responsible for positioning Synairgen as a thought leader in severe respiratory viral infection treatment. Outreach will focus on US, UK & European markets, creating and maintaining connections with PR, IR & PA companies, HCPs, Government and the Pharmaceutical Industry.

Re: ask him why he did not chose to include any type of INF in the analysis

Just gonna take a stab in the dark here, but the title of your post includes 'repurposed therapies'. SNG, which is still working towards approval, does not fit in to this category

Ivermectin trials underway in the Philippines, results expected 2022. Looks messy tbh.

https://www.google.com/amp/s/newsinfo.inquirer.net/1428699/fda-grants-product-registration-for-ivermectin-as-anti-nematode-drug/amp

https://www.google.com/amp/s/newsinfo.inquirer.net/1427571/fda-6-hospitals-now-have-special-permit-to-use-ivermectin/amp

Cheers Guys. Have been watching sng for a long time out of pure interest and finally decided to put my money where my mouth is and invest. My dear mom was 'cured' of hepatitis C by interferon some 20+ years ago so I'm a strong believer in the treatment ??

Hi. New here but came across this today and thought to share.

https://link.springer.com/article/10.1007/s10875-021-01023-5